as having a concomitant infection with C. difficile . Six patients were female and the median age was 49 years (range: 15-80). Six patients with C. difficile infections suffered from UC and 4 patients from CD, all with previous colonic involvement. Eight patients used immunosuppressive therapies; only 2 patients were treated with antibiotics before infection. Conclusion: In contrast to recent reports from other countries, only a low percentage of hospitalized patients with acute flares of their IBD were identified as having an underlying C. difficile infection in this German tertiary referral center. However, in IBD patients with an acute flare, a concomitant C. difficile infection should be excluded, especially in patients with immunosuppressive treatment and colonic involvement of their disease. Further research is needed to evaluate if regions with different risks of C. difficile infections exist and to find out more about potential reasons for this observation.
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tionally, factors like recent use of antibiotics and immu nosuppressive drugs and systemic comorbidities are suggested to increase the risk of C. difficile infection [2] .
After regional outbreaks of C. difficile in the US, Canada and subsequently in parts of Europe, a hypervirulent epidemic strain of C. difficile (North American pulsedfield type 1, PCR ribotype 027) resistant to fluroquinolone attracted a great deal of attention [3] [4] [5] .
As patients with inflammatory bowel disease (IBD) -comprising Crohn's disease (CD) and ulcerative colitis (UC) -frequently present with diarrhea and abdominal pain, differentiation between an acute flare and enteric infection seems to be necessary in this setting. This is even more so since several studies, mainly from the US and Canada, have documented a dramatic rise of C. difficile infections in patients with IBD, both in studies from tertiary referral centers and in national surveys [6] [7] [8] [9] [10] . More recently, an increasing incidence in IBD patients has also been identified in Greece [11] and Belgium [12] , as well as a high prevalence of C. difficile infection in Italian pediatric IBD patients [13] .
However, data on the impact of C. difficile infections in adult IBD patients from other centers in Europe are missing. Therefore, the purpose of this retrospective study was to assess the prevalence of C. difficile infections in patients with IBD in a tertiary center in Germany.
Study Cohort
All in-patients treated for an acute flare of their IBD at the Department of Internal Medicine I of the University of Regensburg between January 1, 2001, and June 30, 2008, were included in this retrospective analysis. Every single admission of a patient was evaluated separately if the patient was admitted to our department more than once. Patients hospitalized only due to disease complications (e.g. fistulas or extraintestinal manifestations), but not suffering from diarrhea, were excluded from this study.
The University of Regensburg is a tertiary referral center which treated 29,162 in-patients in 2007, 3,690 of whom were treated at the Department of Internal Medicine I. IBD patients are referred to this institution from primary care physicians as well as from secondary and primary centers.
The diagnosis of CD, UC or indeterminate colitis was based on endoscopic, histological and radiological findings.
For all patients included in the study, computer-based discharge registries were searched using text searches for ' Clostridium difficile ', ' C. difficile ' or ' C. diff. ' to identify patients with this concomitant diagnosis. Patient records were checked to identify every patient which was tested for C. difficile infection during the relevant hospitalization. The diagnosis of C. difficile infection was made by stool toxin analysis (ELISA stool toxin A and B) and/ or histological evidence with classic pseudomembrane formations.
In patients with a concomitant diagnosis of C. difficile infection, further demographic data such as age, time since first diagnosis of IBD, clinical symptoms, IBD-related treatment at time of infection, nosocomial infection, season at time of infection, treatment for C. difficile infection and outcome were collected.
Statistical analyses were performed using SPSS software (16.0, Chicago, Ill., USA).
Results

Basic Characteristics
During the study period between January 1, 2001, and June 30, 2008, 995 in-patients with IBD were treated in this hospital (638 patients with CD, 357 with UC). In 279 patients with CD and 242 patients with UC, an acute flare with typical symptoms of diarrhea and abdominal pain was the reason for hospital admission. Other reasons for admission were fistulas or extraintestinal manifestations. Patients treated due to disease complications were not included in this analysis.
In all IBD patients with an acute flare, 438 stool tests on pathogenic intestinal bacteria were performed (82.5%). 248 patients were tested particularly with regard to C. difficile by stool toxin analysis (47.6% of all patients), with 120 patients diagnosed as having CD, and 128 patients diagnosed with UC. The number of tests per year in IBD patients with a flare of their disease is presented in table 1 .
In total, 3,267 samples from all the patients treated at the Department of Internal Medicine I -including non-IBD patients -were tested for C. difficile during the study period at the Institute for Microbiology and Hygiene. In 
IBD Patients with C. difficile Infection
Only 10 of all the IBD patients with symptoms of an acute flare with diarrhea were diagnosed as having a concomitant infection with C. difficile (3.9% of all tested IBD patients). In 9 of the 10 patients, the diagnosis of C. difficile infection was confirmed by stool toxin analysis; in 1 patient the diagnosis was made endoscopically and histologically despite negative stool toxin analysis.
Of the 10 patients, 6 were female and the median age was 49 years (range: 15-80). Six patients with C. difficile infections had UC (2.7% of all tested patients with UC). Of the remaining 4 CD patients (4% of all tested patients with CD), 1 patient showed a superinfection with C. difficile at the time of first diagnosis of IBD. In 2 patients, both of whom had UC, the time of first diagnosis of IBD was less than 1 year before infection with C. difficile . In addition, patients with a history of IBD stretching back more than 10 years were affected. Interestingly, in all patients with CD, involvement of the colon was documented ( table 2 ) .
Medication at Time of Infection
Eight patients with concomitant C. difficile infection had immunosuppressive therapies such as corticosteroids (6 patients) or azathioprine (2 patients) at the time of infection. Only 2 patients were treated with antibiotics before C. difficile infection was diagnosed, and one of these patients was simultaneously treated with azathioprine ( fig. 1 
Outcome
All patients were successfully treated with metronidazole, except for the patient with concomitant C. difficile infection at the time of first diagnosis of CD. In this patient, a total proctocolectomy became necessary due to toxic megacolon. All other patients showed remission of symptoms during antibiotic therapy. Additionally, in 7 patients, stool toxin was negative after withdrawal of metronidazole. None of the patients revealed a recurrence of episodes of C. difficile infections after primary treatment.
Discussion
In this retrospective observational study over a 7-year period, we found only a few hospitalized patients with IBD and concomitant C. difficile infection in this tertiary referral center. These results are even more interesting since the incidence of C. difficile infections in the total patient population in this department showed a significant increase during the study period, which is similar to results from other centers. Our observation with regard to IBD patients therefore stands in contrast to several reports, mainly from North America.
An alarming rise in the incidence and prevalence of C. difficile infections in IBD patients has been described both in studies from single tertiary specialty centers and reports using nationwide databases [6] [7] [8] [9] [10] . Worse outcomes and higher mortality were also seen in patients with C. difficile infections and underlying IBD with a rising case fatality during the later years [7, 9] . In our series, we could not find an increase of C. difficile infections in our patients during the observation time in spite of rising awareness of possible infections in the later years. This is In addition, we could not find a seasonal variation of C. difficile infection, although it has been described in previous studies with a lower risk of infection in summer months [8, 14] . A summary of the existing literature on C. difficile infections in IBD patients is given in table 3 . Mylonaki et al. [15] found 5.5% of the relapses in IBD patients to be associated with C. difficile infections in their case series from Great Britain, which is comparable to the results obtained in our retrospective study (3.9% of all tested IBD patients with diarrhea). In contrast to their study, where 60% of the patients with an acute flare were tested for C. difficile toxin, we tested for C. difficile infection in only 48% of the patients with a diarrheal flare. Not testing all the patients with diarrhea has to be considered the main limitation of our study, despite the increasing numbers of patients with acute flares being tested during the later years.
In this context, possible underdiagnosing of C. difficile infection might be caused by the application of antibiotic therapy without prior testing. In our series, a total number of 92 of 521 flares (17.6%) were treated with antibiotic therapy, although no test on C. difficile was performed.
Another limitation was the toxin-based ELISA used for testing in our study, which is known to be less sensitive (70-90%) than cytotoxicity tests. Repeated testing has been shown to increase the diagnostic yield to up to 92-95% [1, 16] . Nevertheless, there are some controversies on repeated testing for C. difficile infection. In their study, Nemat et al. [17] showed a low value of repeated tests, and repeated testing has been suggested to result in false-positive tests [18] . Therefore, a clear guideline recommending the optimal number of tests still does not exist. At our department, initially one test is performed in IBD patients with diarrhea. If the patient does not respond to anti-inflammatory treatment, a second stool test is ordered as well as endoscopic investigations, which led to the diagnosis in one of our patients despite negative stool toxin analysis.
The varying incidence of C. difficile infections in different countries might partly be explained by differences of the examined patient populations. For example, different strategies in the treatment of patients with IBD, e.g. the frequent use of anti-TNF therapies in several countries, might play a role. A previous report identified immunosuppressive therapies as an important predisposing factor for C. difficile infections [19] . This is supported by our results as 80% of our positive patients received immunosuppressive therapy prior to the diagnosis of C. difficile infection. Surprisingly, prior use of antibiotics, which is known as the main cause for C. difficile infection in the general population was only found in 2 patients [2] . Although C. difficile infections may not be limited to the colon [1, 20] , in all of our patients with CD, colonic involvement was seen. Therefore, one may speculate that in addition to UC patients, CD patients with colonic involvement are at a higher risk for C. difficile infection. This observation is consistent with results of earlier studies identifying colonic disease as a risk factor for C. difficile infection [8, 9] .
Conclusion
In this German tertiary referral center only a low percentage of hospitalized patients with IBD were found to have a concomitant C. difficile infection. Therefore, in contrast to reports from North America and Belgium, IBD patients hospitalized due to an acute flare have only a moderate risk for C. difficile infection in our region. This observation suggests the possibility that low-and high-risk areas for C. difficile infections might exist. As this is the first study showing possible geographic variation, further research on underlying reasons is needed.
Nevertheless, in clinical practice in all IBD patients with an acute diarrheal flare, a superinfection with C. difficile should be excluded. This is of special importance in patients with immunosuppressive treatment and colonic involvement to prevent medical malpractice using detrimental immunosuppressive therapies in C. difficile -infected IBD patients, shorten the time of hospitalization and improve patient outcome.
